<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="499c8533-8d90-4069-b9fc-1265189d5689"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use </content>
      <content styleCode="bold">FERRIPROX</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">Tablets</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">safely</content>
      <content styleCode="bold"> and effectively. See full prescribing information for </content>
      <content styleCode="bold">FERRIPROX</content>
      <content styleCode="bold"> </content>
      <content styleCode="bold">Tablets</content>
      <content styleCode="bold">.</content>
      <br/>
      <content styleCode="bold">FERRIPROX</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> (deferiprone) </content>
      <content styleCode="bold">tablets</content>
      <content styleCode="bold">, for oral use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: </content>
      <content styleCode="bold">2011</content>
      <br/>
   </title>
   <effectiveTime value="20250331"/>
   <setId root="946718ff-df43-1baa-74d1-e5bcfbe8ad86"/>
   <versionNumber value="13"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="088084228" root="1.3.6.1.4.1.519.1"/>
            <name>Chiesi USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="73cfb439-0e1c-4ef2-b436-6f828b8300cc"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250415"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="10122-104" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FERRIPROX</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>deferiprone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1000"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFERIPRONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFERIPRONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3A3U0GI71G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NX76LV5T8J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6N003M473W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2/S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="10122-104-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200519"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="10122-104-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211201"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA212269" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200519"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">FPX;DR;APO;1000</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="21" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="10122-103" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FERRIPROX</name>
                        <formCode code="C42931" displayName="TABLET, FILM COATED" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>DEFERIPRONE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1000"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFERIPRONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFERIPRONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NPU9M2E6L8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLCELLULOSE (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="10122-103-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190801"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021825" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190801"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;1000</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="10122-100" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FERRIPROX</name>
                        <formCode code="C42931" displayName="TABLET, FILM COATED" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>deferiprone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEFERIPRONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2BTY8KH53L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DEFERIPRONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="288VBX44JC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="10122-100-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20210101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA021825" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20111125"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">APO;500</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_eba5d893-c50b-444f-9788-98a585f46d38">
               <id root="380c4ce5-6a5c-4abc-bb0d-9c02d775293f"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <text/>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td>Warnings and Precautions, Agranulocytosis and Neutropenia (<linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>)</td>
                                 <td>3/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ff5cddd6-060e-4518-b4df-196f39ee40a7">
               <id root="06c89de5-f807-4175-a9cc-7109dc14c819"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="bold">WARNING: AGRANULOCYTOSIS AND NEUTROPENIA</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">•</content>
                     <content styleCode="bold">
		     
	FERRIPROX can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. </content>
                     <content styleCode="bold">
                        <content styleCode="italics">[see Warnings and Precautions (</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                        </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">)]</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">•</content>
                     <content styleCode="bold">
		     
	Measure the absolute neutrophil count (ANC) before starting FERRIPROX therapy and monitor regularly while on therapy.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">•</content>
                     <content styleCode="bold">
		     
	Interrupt FERRIPROX therapy if neutropenia develops. </content>
                     <content styleCode="bold">
                        <content styleCode="italics">[see Warnings and Precautions (</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                        </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">)]</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">•</content>
                     <content styleCode="bold">
		     
	Interrupt FERRIPROX if infection develops, and monitor the ANC more frequently. </content>
                     <content styleCode="bold">
                        <content styleCode="italics">[see Warnings and Precautions (</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                        </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">)]</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">•</content>
                     <content styleCode="bold">
		     
	Advise patients taking FERRIPROX to report immediately any symptoms indicative of infection. </content>
                     <content styleCode="bold">
                        <content styleCode="italics">[see Warnings and Precautions (</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                        </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">)]</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: AGRANULOCYTOSIS AND NEUTROPENIA</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•</content>
                           <content styleCode="bold">
		     
	FERRIPROX can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis. (</content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•</content>
                           <content styleCode="bold">
		     
	Measure the absolute neutrophil count (ANC) before starting FERRIPROX and monitor regularly while on therapy. (</content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•</content>
                           <content styleCode="bold">
		     
	Interrupt FERRIPROX therapy if neutropenia develops. (</content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•</content>
                           <content styleCode="bold">
		     
	Interrupt FERRIPROX if infection develops and monitor the ANC more frequently. (</content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">)</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">•</content>
                           <content styleCode="bold">
		     
	Advise patients taking FERRIPROX to report immediately any symptoms indicative of infection. (</content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_dde09d7d-ba4c-45fa-9021-9432489e719f">
               <id root="573b3d60-7627-488c-9472-fd453b46fb41"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
                  <content styleCode="bold">
     
INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>FERRIPROX Tablets are indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias.</paragraph>
                  <paragraph>
     
<content styleCode="underline">Limitation</content>
                     <content styleCode="underline">s</content>
                     <content styleCode="underline"> of Use</content>
                  </paragraph>
                  <paragraph>• Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>FERRIPROX Tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. (<linkHtml href="#LINK_dde09d7d-ba4c-45fa-9021-9432489e719f">1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitation</content>
                           <content styleCode="underline">s</content>
                           <content styleCode="underline"> of Use</content>
                        </paragraph>
                        <paragraph>Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8c06aeba-5cf6-49ba-9133-a39148da65c4">
               <id root="9a838818-0715-49a2-ab74-20f700c24a27"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2</content>
                  <content styleCode="bold">
		     
	DOSAGE AND ADMINISTRATION</content>
               </title>
               <text/>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>FERRIPROX Tablets are available in three formulations. Two different 1,000 mg formulations, and a 500 mg formulation, which have different dosing regimens to achieve the same total daily dosage. (<linkHtml href="#LINK_29e05553-1069-41b4-9417-20fee276aa23">2.1</linkHtml>)<br/>
                           </item>
                           <item>To prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen. Each tablet has distinct identifying characteristics. (<linkHtml href="#LINK_29e05553-1069-41b4-9417-20fee276aa23">2.1</linkHtml>, <linkHtml href="#LINK_65d85fcc-8f04-4a85-9439-be020e1742a2">3</linkHtml>)<br/>
                           </item>
                           <item>FERRIPROX Tablets (twice a day), 1,000 mg: <br/>• Starting oral dosage: 75 mg/kg/day (actual body weight) in two divided doses (<linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>)<br/>• Maximum oral dosage: 99 mg/kg/day (actual body weight) in two divided doses (<linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>)<br/>
                           </item>
                           <item>FERRIPROX Tablets (three times a day), 1,000 mg: <br/>○ Starting oral dosage: 75 mg/kg/day (actual body weight) in three divided doses (<linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>)<br/>○ Maximum oral dosage: 99 mg/kg/day (actual body weight) in three divided doses (<linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>)<br/>
                           </item>
                           <item>FERRIPROX Tablets (three times a day), 500 mg: <br/>○ Starting oral dosage: 75 mg/kg/day (actual body weight) in three divided doses (<linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>)<br/>○ Maximum oral dosage: 99 mg/kg/day (actual body weight) in three divided doses (<linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_29e05553-1069-41b4-9417-20fee276aa23">
                     <id root="7573fba1-9f2f-4348-9aff-e63b04238b9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1</content>
     
<content styleCode="bold">Important Dosage and Administration Information</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">FERRIPRO</content>
                           <content styleCode="bold">X</content>
                           <content styleCode="bold"> T</content>
                           <content styleCode="bold">ablets</content>
                           <content styleCode="bold"> </content>
                           <content styleCode="bold">are</content>
                           <content styleCode="bold"> available in two different 1,000 mg formulations</content>
                           <content styleCode="bold"> and a 500 mg </content>
                           <content styleCode="bold">formulation</content>
                           <content styleCode="bold">, which have different oral dosing regimens to achieve the same total daily dosage.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>FERRIPROX Tablets (twice a day) - 1,000 mg - given two times a day <content styleCode="italics">[see Dosage and Administration (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>
                           </item>
                           <item>FERRIPROX Tablets (three times a day) - 1,000 mg - given three times a day <content styleCode="italics">[see Dosage and Administration (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_8df2bafa-47f8-4518-8d9c-e14381fc0d08">2.3</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>
                           </item>
                           <item>FERRIPROX Tablets - 500 mg - given three times a day <content styleCode="italics">[see Dosage and Administration (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_6fcc9ada-1f48-4847-83a6-b4d14f18c8b1">2.4</linkHtml>
                              </content>
                              <content styleCode="italics">)]</content>
                           </item>
                        </list>
                        <paragraph>To prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen. Each tablet has distinct identifying characteristics <content styleCode="italics">[see Dosage Forms and Strengths (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_65d85fcc-8f04-4a85-9439-be020e1742a2">3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>For patients who have trouble swallowing tablets, consider the use of FERRIPROX Oral Solution (see the prescribing information for FERRIPROX Oral Solution).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Monitoring for Safety</content>
                        </paragraph>
                        <paragraph>Due to the risk of agranulocytosis, monitor ANC before and during FERRIPROX therapy.</paragraph>
                        <paragraph>Test ANC prior to start of FERRIPROX therapy and monitor on the following schedule during treatment:</paragraph>
                        <paragraph>• First six months of therapy: Monitor ANC weekly;</paragraph>
                        <paragraph>• Next six months of therapy: Monitor ANC once every two weeks;</paragraph>
                        <paragraph>• After one year of therapy: Monitor ANC every two to four weeks (or at the patient’s blood transfusion interval in patients that have not experienced an interruption due to any decrease in ANC <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>Due to the risk of hepatic transaminase elevations, monitor ALT before and monthly during FERRIPROX therapy <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_5c74c56f-0e35-4103-8e44-45fb736c46c8">5.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>Due to the risk of zinc deficiency, monitor zinc levels before and regularly during FERRIPROX therapy <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3cb3a25c-be0b-4e91-8624-68d4e46eae8e">5.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">
                     <id root="1ad08bc4-0492-4d41-89db-60941a309766"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2</content>
		     
	<content styleCode="bold">Recommended</content>
                        <content styleCode="bold"> Dosage for 1,000 mg</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">FERRIPROX</content>
                        <content styleCode="bold"> T</content>
                        <content styleCode="bold">ablets</content>
                        <content styleCode="bold"> (</content>
                        <content styleCode="bold">twice a day) for Adult and Pediatric Patients with Transfusional Iron Overload due to Thalassemia Syndromes, Sickle Cell Disease or Other Anemias</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Starting Dos</content>
                           <content styleCode="underline">ag</content>
                           <content styleCode="underline">e</content>
                           <content styleCode="underline"> </content>
                           <content styleCode="underline">for T</content>
                           <content styleCode="underline">wice</content>
                           <content styleCode="underline"> </content>
                           <content styleCode="underline">a </content>
                           <content styleCode="underline">Day Tablets</content>
                        </paragraph>
                        <paragraph>The recommended starting oral dosage of FERRIPROX Tablets (twice a day) is 75 mg/kg/day (actual body weight) in two divided doses per day (taken approximately 12 hours apart), with food. Round the total daily dose to the nearest 500 mg (half-tablet). Table 1 describes the number of FERRIPROX Tablets (twice a day) needed to achieve the 75 mg/kg/day total starting daily dosage. </paragraph>
                        <table>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Table </content>
                                    <content styleCode="bold">1</content>
                                    <content styleCode="bold">:</content> 
		     
	<content styleCode="bold">Number of </content>
                                    <content styleCode="bold">FERRIPROX </content>
                                    <content styleCode="bold">1,000 mg </content>
                                    <content styleCode="bold">T</content>
                                    <content styleCode="bold">ablets</content>
                                    <content styleCode="bold"> (twice a day)</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Needed to Achieve the Total Starting Daily Dosage of 75</content>
                                    <content styleCode="bold"> mg/k</content>
                                    <content styleCode="bold">g</content>
                                    <content styleCode="bold"> (rounded to the nearest half-tablet)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Body Weight</content>
                                    <br/>
                                    <content styleCode="bold">(kg)</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Morning</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Evening</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">0.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">30</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">40</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">50</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">60</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">70</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">80</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">90</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>To minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dos</content>
                           <content styleCode="underline">ag</content>
                           <content styleCode="underline">e Adjustment</content>
                           <content styleCode="underline">s</content>
                           <content styleCode="underline"> for T</content>
                           <content styleCode="underline">wice</content>
                           <content styleCode="underline"> </content>
                           <content styleCode="underline">a Day </content>
                           <content styleCode="underline">Tablets</content>
                        </paragraph>
                        <paragraph>Tailor dosage adjustments of FERRIPROX Tablets (twice a day) to the individual patient’s response and therapeutic goals (maintenance or reduction of body iron burden). The maximum total daily oral dosage is 99 mg/kg (actual body weight) divided into two doses taken approximately 12 hours apart with food. Table 2 describes the number of FERRIPROX Tablets (twice a day) needed to achieve the 99 mg/day total maximum daily dosage.</paragraph>
                        <table>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="3" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Table </content>
                                    <content styleCode="bold">2</content>
                                    <content styleCode="bold">:</content>
                                    <content styleCode="bold"> </content>
		     
	<content styleCode="bold">Number of FERRIPROX </content>
                                    <content styleCode="bold">1,000 mg </content>
                                    <content styleCode="bold">Tablets</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">(twice a day) Needed to A</content>
                                    <content styleCode="bold">chieve a</content>
                                    <content styleCode="bold"> Total Maximum Recommended Daily Dosage of 99 mg/kg (rounded to the nearest half-tablet)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Body Weight</content>
                                    <br/>
                                    <content styleCode="bold">(kg)</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Morning</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Evening</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">30</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">40</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">50</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">60</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">70</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">80</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">90</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4.5</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8df2bafa-47f8-4518-8d9c-e14381fc0d08">
                     <id root="236cc1fe-a866-494d-9cae-1f3fe37ecfbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2</content>
                        <content styleCode="bold">.3</content>
		     
	<content styleCode="bold">Recommended </content>
                        <content styleCode="bold">Dos</content>
                        <content styleCode="bold">age</content>
                        <content styleCode="bold"> for </content>
                        <content styleCode="bold">1,000 mg </content>
                        <content styleCode="bold">FERRIPROX</content>
                        <content styleCode="bold"> T</content>
                        <content styleCode="bold">ablets</content>
                        <content styleCode="bold"> (three times a day)</content>
                        <content styleCode="bold"> for Adult and Pediatric Patients</content>
                        <content styleCode="bold"> with Transfusional Iron Overload due to Thalassemia Syndromes, Sickle Cell Disease or Other Anemias</content>
                        <content styleCode="bold"> </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Starting Dos</content>
                           <content styleCode="underline">ag</content>
                           <content styleCode="underline">e</content>
                           <content styleCode="underline"> for Three Times a Day Tablets</content>
                        </paragraph>
                        <paragraph>The recommended starting oral dosage of FERRIPROX Tablets (three times a day) is 75 mg/kg/day (actual body weight), in three divided doses per day. Table 3 describes the number of FERRIPROX Tablets (three times a day) needed to achieve the 75 mg/kg/day total starting dosage). Round dose to the nearest 500 mg (half-tablet).</paragraph>
                        <table>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="4" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Table </content>
                                    <content styleCode="bold">3</content>
                                    <content styleCode="bold">: </content>
		     
	<content styleCode="bold">Number of </content>
                                    <content styleCode="bold">F</content>
                                    <content styleCode="bold">ERRIPROX </content>
                                    <content styleCode="bold">1,000 mg </content>
                                    <content styleCode="bold">T</content>
                                    <content styleCode="bold">ablets</content>
                                    <content styleCode="bold"> (three times </content>
                                    <content styleCode="bold">a </content>
                                    <content styleCode="bold">day)</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Needed to Achieve the Total Starting Daily Dosage of</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">75 </content>
                                    <content styleCode="bold">mg/kg (rounded to the nearest half-tablet)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Body Weight</content>
                                    <br/>
                                    <content styleCode="bold">(kg)</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Morning</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Midday</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Evening</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">0.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">0.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">0.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">30</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">0.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">40</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">50</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">60</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">70</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">80</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">90</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>To minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dosage Adjustments</content>
                           <content styleCode="underline"> </content>
                           <content styleCode="underline">for Three Times Daily Tablets</content>
                        </paragraph>
                        <paragraph>Tailor dosage adjustments for FERRIPROX Tablets (three times a day) to the individual patient’s response and therapeutic goals (maintenance or reduction of body iron burden). The maximum oral dosage is 99 mg/kg/day (actual body weight), in three divided doses per day. Table 4 describes the number of FERRIPROX Tablets (three times a day) needed to achieve the 99 mg/day total maximum daily dosage.</paragraph>
                        <table>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="4" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Table 4: </content>
		     
	<content styleCode="bold">Number of FERRIPROX 1,000 mg Tablets (three times a day) Needed to Achieve the Maximum Total Daily Dosage of 99 mg/kg (rounded to the nearest half-tablet)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Body Weight</content>
                                    <br/>
                                    <content styleCode="bold">(kg)</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Morning</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Midday</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Evening</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">0.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">0.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">30</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">40</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">50</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">60</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">70</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">80</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">90</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6fcc9ada-1f48-4847-83a6-b4d14f18c8b1">
                     <id root="3bf78bbc-dce6-435e-a859-1ce9d7c2b564"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">4</content>
                        <content styleCode="bold">
     
Recommended Dosage for 500 mg FERRIPROX Tablets</content>
                        <content styleCode="bold"> (three times a day)</content>
                        <content styleCode="bold"> for Adult and Pediatric Patients with Transfusional Iron Overload due to Thalassemia Syndromes, Sickle Cell Disease or Other Anemias</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Starting </content>
                           <content styleCode="underline">Dos</content>
                           <content styleCode="underline">ag</content>
                           <content styleCode="underline">e</content> <content styleCode="underline">for Three Times a Day Tablets</content>
                        </paragraph>
                        <paragraph>The recommended starting oral dosage of FERRIPROX Tablets (three times a day) is 75 mg/kg/day (actual body weight), in three divided doses per day. Table 5 describes the number of FERRIPROX Tablets (three times a day) needed to achieve the 75 mg/kg/day total starting dosage. Round dose to the nearest 250 mg (half-tablet).</paragraph>
                        <table>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="4" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Table 5: </content>
                 
            <content styleCode="bold">Number of FERRIPROX 500 mg Tablets (three times a day) Needed to Achieve the Total Starting Daily Dosage of 75 mg/kg dose (rounded to the nearest half-tablet)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Body Weight</content>
                                    <br/>
                                    <content styleCode="bold">(kg)</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Morning</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Midday</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Evening</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">30</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">40</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">50</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">60</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">70</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">80</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">90</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>To minimize gastrointestinal upset when first starting therapy, dosing can start at 45 mg/kg/day and increase weekly by 15 mg/kg/day increments until the full prescribed dose is achieved.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dos</content>
                           <content styleCode="underline">ag</content>
                           <content styleCode="underline">e</content>
                           <content styleCode="underline"> Adjustments</content>
                        </paragraph>
                        <paragraph>Tailor dosage adjustments for FERRIPROX Tablets (three times a day) to the individual patient’s response and therapeutic goals (maintenance or reduction of body iron burden). The maximum oral dosage is 99 mg/kg/day (actual body weight), in three divided doses per day. Table 6 describes the number of FERRIPROX Tablets (three times a day) needed to achieve the 99 mg/day total maximum daily dosage.</paragraph>
                        <table>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="4" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Table </content>
                                    <content styleCode="bold">6</content>
                                    <content styleCode="bold">: </content>
                 
            <content styleCode="bold">Number of FERRIPROX 500 mg </content>
                                    <content styleCode="bold">Tablets (three times a day) Needed </content>
                                    <content styleCode="bold">to </content>
                                    <content styleCode="bold">Achieve the Maximum Total Daily Dosage of 99</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">mg/kg </content>
                                    <content styleCode="bold">dose </content>
                                    <content styleCode="bold">(rounded to the nearest half-tablet)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Body Weight</content>
                                    <br/>
                                    <content styleCode="bold">(kg)</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Morning</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Midday</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Evening</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">1.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">30</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">40</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">2</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">50</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">60</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">70</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">80</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">5.5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">5.5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">90</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">6</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">6</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">6</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241031"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8929d100-a1e5-40a5-a0d1-11c6fabf1d4e">
                     <id root="e8287b60-8e20-4b2f-8b1c-f5a077b175ba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">5</content>
                        <content styleCode="bold">
		     
	Monitoring Ferritin Levels to Assess Efficacy</content>
                     </title>
                     <text>
                        <paragraph>Monitor serum ferritin concentration every two to three months to assess the effect of FERRIPROX on body iron stores. If the serum ferritin is consistently below 500 mcg/L, consider temporarily interrupting FERRIPROX therapy until serum ferritin rises above 500 mcg/L.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3a04fcf6-acb3-426c-9713-0e1228523e3c">
                     <id root="49822a35-430f-41e9-9879-d33d95b9dc76"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.</content>
                        <content styleCode="bold">6</content>
		     
	<content styleCode="bold">Dosage Modification for Drug Interactions</content>
                     </title>
                     <text>
                        <paragraph>Allow at least a 4-hour interval between administration of FERRIPROX and other drugs or supplements containing polyvalent cations such as iron, aluminum, or zinc <content styleCode="italics">[</content>
                           <content styleCode="italics">see</content>
                           <content styleCode="italics"> Drug Interactions</content>
                           <content styleCode="italics"> </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_243d97dc-d02d-4072-97ab-30231a286638">7.2</linkHtml>
                           </content>
                           <content styleCode="italics">),</content>
                           <content styleCode="italics"> </content>
                           <content styleCode="italics">Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_372a6d7c-ec99-445b-9366-b5ac496e5db0">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_65d85fcc-8f04-4a85-9439-be020e1742a2">
               <id root="5ea85d71-307e-468d-b5c5-a35da03938de"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3</content>
                  <content styleCode="bold">
		     
	DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <list listType="unordered" styleCode="Disk">
                     <item>Tablets (twice a day): 1,000 mg, capsule-shaped, white to off-white tablets with functional scoring, engraved “FPX” bisect “DR” on one side, “APO” bisect “1000” on the other”. <br/>
                     </item>
                     <item>Tablets (three times a day): 1,000 mg film-coated, capsule-shaped, white to off-white tablets with functional scoring, and imprinted with “APO” score “1000” on one side and plain on the other.<br/>
                     </item>
                     <item>Tablets: 500 mg film-coated, capsule-shaped, white to off-white tablets with functional scoring, and imprinted with “APO” score “500” on one side and plain on the other.</item>
                  </list>
               </text>
               <effectiveTime value="20230701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Tablets (twice a day): 1,000 mg with functional scoring (<linkHtml href="#LINK_65d85fcc-8f04-4a85-9439-be020e1742a2">3</linkHtml>)<br/>
                           </item>
                           <item>Tablets (three times a day): 1,000 mg with functional scoring (<linkHtml href="#LINK_65d85fcc-8f04-4a85-9439-be020e1742a2">3</linkHtml>)<br/>
                           </item>
                           <item>Tablets (three times a day): 500 mg with functional scoring (<linkHtml href="#LINK_65d85fcc-8f04-4a85-9439-be020e1742a2">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_17659082-7969-4232-b500-b2ff422fd21b">
               <id root="5bda64ca-63f2-4b07-9d2e-f78216d2940e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
                  <content styleCode="bold">
		     
	CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>FERRIPROX is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulations. The following reactions have been reported in association with the administration of deferiprone: Henoch-Schönlein purpura; urticaria; and periorbital edema with skin rash <content styleCode="italics">[</content>
                     <content styleCode="italics">see </content>
                     <content styleCode="italics">Adverse Reactions</content>
                     <content styleCode="italics"> (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_1ddddf52-1507-4ce0-9a06-de41c1ae73a6">6.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>
                     <content styleCode="italics">.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to deferiprone or to any of the excipients in the formulations. (<linkHtml href="#LINK_17659082-7969-4232-b500-b2ff422fd21b">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_304bd951-2baf-40ee-881d-e7b93c4788bb">
               <id root="8b0519f1-b5f5-4a43-bf19-9374bf6674b7"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
                  <content styleCode="bold">
		     
	WARNINGS AND PRECAUTIONS</content>
               </title>
               <text/>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Liver Enzyme Elevations: Monitor monthly and discontinue for persistent elevations. (<linkHtml href="#LINK_5c74c56f-0e35-4103-8e44-45fb736c46c8">5.2</linkHtml>)<br/>
                           </item>
                           <item>Zinc Deficiency: Monitor during therapy and supplement for deficiency. (<linkHtml href="#LINK_3cb3a25c-be0b-4e91-8624-68d4e46eae8e">5.3</linkHtml>)<br/>
                           </item>
                           <item>Embryo-Fetal Toxicity: Can cause fetal harm. (<linkHtml href="#LINK_f2b9c274-313f-4d26-bb21-270fbb116b0a">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">
                     <id root="70eca1a9-c8c6-4620-a2a9-efbfab44ce5f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1</content>
     
<content styleCode="bold">Agranulocytosis and </content>
                        <content styleCode="bold">Neutropenia</content>
                     </title>
                     <text>
                        <paragraph>Fatal agranulocytosis can occur with FERRIPROX use. FERRIPROX can also cause neutropenia, which may foreshadow agranulocytosis. Measure the absolute neutrophil count (ANC) before starting FERRIPROX therapy and monitor it regularly while on therapy <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_29e05553-1069-41b4-9417-20fee276aa23">2.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>Reduction in the frequency of ANC monitoring should be considered on an individual patient basis, according to the health care provider’s assessment of the patient’s understanding of the risk minimization measures required during therapy.</paragraph>
                        <paragraph>Interrupt FERRIPROX therapy if neutropenia develops (ANC &lt; 1.5 x 10<sup>9</sup>/L).</paragraph>
                        <paragraph>Interrupt FERRIPROX if infection develops and monitor the ANC frequently.</paragraph>
                        <paragraph>Advise patients taking FERRIPROX to immediately interrupt therapy and report to their physician if they experience any symptoms indicative of infection.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The incidence of agranulocytosis was 1% of patients in pooled clinical trials of 642 patients with thalassemia syndromes and 0.5% of patients in pooled clinical trials of 196 patients with sickle cell disease or other anemias. The mechanism of FERRIPROX-associated agranulocytosis is unknown. Agranulocytosis and neutropenia usually resolve upon discontinuation of FERRIPROX, but there have been reports of agranulocytosis leading to death.</content>
                        </paragraph>
                        <paragraph>Implement a plan to monitor for and to manage agranulocytosis and neutropenia prior to initiating FERRIPROX treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section ID="LINK_6ed11e52-de09-47c9-b74a-2fa6d72da4ee">
                           <id root="ca267af2-b149-483b-a918-e80e4a1fdbd3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <br/>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange underline">For agranulocytosis (ANC &lt; 0.2 x 10<sup>9</sup>/L) and severe neutropenia (0.2 x 10<sup>9</sup>/L ≤ ANC &lt; 0.5 x 10<sup>9</sup>/L):</content>
                              </paragraph>
                              <paragraph>Consider hospitalization and other management as clinically appropriate.</paragraph>
                              <paragraph>Do not resume FERRIPROX in patients who have developed agranulocytosis unless potential benefits outweigh potential risks.<content styleCode="italics"> </content>Do not rechallenge patients who have developed neutropenia with FERRIPROX unless potential benefits outweigh potential risks.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_ad9b7bd4-a479-45d4-b24f-1bfb6c722a0d">
                           <id root="ba0914c5-b0f9-4e44-a8ae-c4a286873498"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <br/>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange underline">For neutropenia (ANC &lt; 1.5 x 10<sup>9</sup>/L and ≥ 0.5 x 10<sup>9</sup>/L):</content>
                              </paragraph>
                              <paragraph>Instruct the patient to immediately discontinue FERRIPROX and all other medications with a potential to cause neutropenia.</paragraph>
                              <paragraph>Obtain a complete blood cell (CBC) count, including a white blood cell (WBC) count corrected for the presence of nucleated red blood cells, an absolute neutrophil count (ANC), and a platelet count daily until recovery (ANC ≥ 1.5 x 10<sup>9</sup>/L).</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5c74c56f-0e35-4103-8e44-45fb736c46c8">
                     <id root="59dee46b-126e-474d-937f-d841e0ef8ce4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">2</content>
		     
	<content styleCode="bold">Liver Enzyme Elevations</content>
                     </title>
                     <text>
                        <paragraph>In pooled clinical trials, 7.5% of 642 patients with thalassemia syndromes treated with FERRIPROX developed increased ALT values. Four (0.62%) FERRIPROX-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST. In pooled clinical trials, 7.7% of 196 patients with sickle cell disease or other anemias treated with FERRIPROX developed increased ALT values.</paragraph>
                        <paragraph>Monitor serum ALT values monthly during therapy with FERRIPROX and consider interruption of therapy if there is a persistent increase in the serum transaminase levels <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_29e05553-1069-41b4-9417-20fee276aa23">2.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3cb3a25c-be0b-4e91-8624-68d4e46eae8e">
                     <id root="cccf49ca-f4ab-4e96-9ffb-4f64ebd5f270"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">3</content>
		     
	<content styleCode="bold">Zinc Deficiency</content>
                     </title>
                     <text>
                        <paragraph>Decreased plasma zinc concentrations have been observed on FERRIPROX therapy. Monitor plasma zinc annually, and supplement in the event of a deficiency <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_29e05553-1069-41b4-9417-20fee276aa23">2.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f2b9c274-313f-4d26-bb21-270fbb116b0a">
                     <id root="0eaf9c2e-4f8e-4943-bbe1-097b86dd9756"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4</content>
		     
	<content styleCode="bold">Embryo</content>
                        <content styleCode="bold">-F</content>
                        <content styleCode="bold">etal Toxicity</content>
                     </title>
                     <text>
                        <paragraph>Based on findings from animal reproduction studies and evidence of genotoxicity, FERRIPROX can cause fetal harm when administered to a pregnant woman. The available data on the use of FERRIPROX in pregnant women are insufficient to inform risk. In animal studies, administration of deferiprone during the period of organogenesis resulted in embryo-fetal death and malformations at doses lower than equivalent human clinical doses. Advise pregnant women and females of reproductive potential of the potential risk to the fetus <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_c7ee98dc-4a70-4f68-8649-e46975094440">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>Advise females of reproductive potential to use an effective method of contraception during treatment with FERRIPROX and for at least six months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with FERRIPROX and for at least three months after the last dose <content styleCode="italics">[</content>
                           <content styleCode="italics">see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_c7ee98dc-4a70-4f68-8649-e46975094440">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_74dcb2ac-90d7-495b-8ede-fb5379dbed7e">8.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0f0b148e-4046-4acc-b592-8105028158ee">
               <id root="d0d5ecc5-431b-4401-9506-fda2e205d2d4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
                  <content styleCode="bold">
		     
	ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described below and elsewhere in the labeling: </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Agranulocytosis and Neutropenia <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Liver Enzyme Elevations <content styleCode="italics">[</content>
                        <content styleCode="italics">see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_5c74c56f-0e35-4103-8e44-45fb736c46c8">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)</content>
                        <content styleCode="italics">]</content>
                        <br/>
                     </item>
                     <item>Zinc Deficiency <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_3cb3a25c-be0b-4e91-8624-68d4e46eae8e">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>The most common adverse reactions in patients with thalassemia (incidence ≥ 6%) are nausea, vomiting, abdominal pain, arthralgia, ALT increased and neutropenia. (<linkHtml href="#LINK_0f0b148e-4046-4acc-b592-8105028158ee">6</linkHtml>)<br/>
                           </item>
                           <item>The most common adverse reactions in patients with sickle cell disease or other anemias (incidence ≥6%) are pyrexia, abdominal pain, bone pain, headache, vomiting, pain in extremity, sickle cell anemia with crisis, back pain, ALT increased, AST increased, arthralgia, oropharyngeal pain, nasopharyngitis, neutrophil count decreased, cough and nausea. (<linkHtml href="#LINK_0f0b148e-4046-4acc-b592-8105028158ee">6</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA, Inc. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_fea5eb86-d687-484c-8e48-fd013c0d0d17">
                     <id root="6fcff0d0-a535-4a7a-9d30-33b3b8a41873"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">6.1</content>
                        <content styleCode="bold">
     
Clinical Trial Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>FERRIPROX Tablets (twice a day) were evaluated in trials in healthy subjects. FERRIPROX Tablets (twice a day) contain deferiprone, the same active ingredient as FERRIPROX Tablets (deferiprone) (three times a day) and FERRIPROX Oral Solution (deferiprone). </paragraph>
                        <paragraph>The following adverse reaction information represents the pooled data collected from single arm or active-controlled clinical trials with FERRIPROX Tablets (deferiprone) (three times a day) or FERRIPROX Oral Solution (deferiprone).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Thalassemia Syndromes</content>
                        </paragraph>
                        <paragraph>The safety of FERRIPROX was evaluated in the pooled clinical trial database <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_fc89c9f2-16e4-4e81-aadf-79e4a7834d61">14.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Patients received FERRIPROX Tablets (three times a day) or FERRIPROX Oral Solution . FERRIPROX was administered orally three times a day (total daily dose either 50, 75, or 99 mg/kg), N=642. Among 642 patients receiving FERRIPROX, 492 (76.6%) were exposed for 6 months or longer and 365 (56.9%) were exposed for greater than one year.</paragraph>
                        <paragraph>The median age of patients who received FERRIPROX was 19 years (range 1, 77 years); 50.2% female; 71.2% White, 17.8% Asian, 9.2% Unknown, 1.2% Multi-racial and 0.6% Black.</paragraph>
                        <paragraph>The most serious adverse reaction reported in clinical trials with FERRIPROX was agranulocytosis <content styleCode="italics">[see </content>
                           <content styleCode="italics">Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>The most common adverse reactions (≥6%) reported during clinical trials were nausea, vomiting, abdominal pain, arthralgia, alanine aminotransferase increased and neutropenia.</paragraph>
                        <paragraph>The table below lists the adverse drug reactions that occurred in at least 1% of patients treated with FERRIPROX in clinical trials in patients with thalassemia syndromes.</paragraph>
                        <table>
                           <caption>Table 7:
         
    Adverse reactions occurring in ≥ 1% of FERRIPROX-treated patients with thalassemia syndromes</caption>
                           <col width="317"/>
                           <col width="162"/>
                           <tbody>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Body System</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">(N=642)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Lrule Rrule">
                                    <content styleCode="bold">     </content>
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Lrule Rrule">
                                    <content styleCode="bold">% </content>
                                    <content styleCode="bold">Patients</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">BLOOD AND LYMPHATIC SYSTEM DISORDERS</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Neutropenia<sup>*</sup>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">7</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Agranulocytosis<sup>†</sup>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">GASTROINTESTINAL DISORDERS</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Nausea</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">13</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Abdominal pain/discomfort</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">10</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Vomiting</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">10</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Diarrhea</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">3</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Dyspepsia</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">INVESTIGATIONS</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Alanine aminotransferase increased </td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">7</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Weight increased</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Aspartate aminotransferase increased</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">METABOLISM AND NUTRITION </content>
                                    <br/>
                                    <content styleCode="bold">DISORDERS</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Increased appetite</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">4</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Decreased appetite</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">MUSCULOSKELETAL AND </content>
                                    <br/>
                                    <content styleCode="bold">CONNECTIVE</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">TISSUE </content>
                                    <br/>
                                    <content styleCode="bold">DISORDERS</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Arthralgia</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">10</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Back pain</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Pain in extremity</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">    Arthropathy</td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule">1</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">NERVOUS SYSTEM DISORDERS</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">    Headache</td>
                                 <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule">2</td>
                              </tr>
                              <tr>
                                 <td colspan="2"> <sup>*</sup>Neutropenia includes events of severe neutropenia (ANC ≥0.2 x 10<sup>9</sup>/L and &lt;0.5 x 10<sup>9</sup>/L).<br/>
            †Agranulocytosis (ANC&lt; 0.2 x 10<sup>9</sup>/L)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Gastrointestinal symptoms such as nausea, vomiting, and abdominal pain were the most frequent adverse reactions reported by patients participating in clinical trials and led to the discontinuation of FERRIPROX therapy in 1.6% of patients.</paragraph>
                        <paragraph>Chromaturia (reddish/brown discoloration of the urine) is a result of the excretion of iron in the urine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Sickle Cell Disease or Other Anemias</content>
                        </paragraph>
                        <paragraph>The safety of FERRIPROX compared to deferoxamine was evaluated in LA38-0411 <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_398e829a-3c5e-4695-961a-bb76e4f20664">14.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Patients received FERRIPROX Tablets or FERRIPROX Oral Solution orally three times a day (total daily dose 75-99 mg/kg/day) n=152) or the control arm, deferoxamine, 20-40 mg/kg/day (children) or 40-50 mg/kg/day (adults), by subcutaneous infusion for 5 – 7 days per week, n=76. Among 152 patients receiving FERRIPROX, 120 (78.9%) were exposed for 6 months or longer and 17 (11.2%) were exposed for greater than one year.</paragraph>
                        <paragraph>The median age of patients who received FERRIPROX was 15 years (range 3, 59 years); 54.6% male; 78.9% White, 15.1% Black and 5.9% Multi-racial.</paragraph>
                        <paragraph>The most common adverse reactions (≥6%) reported during clinical trials in patients with SCD or other anemias were pyrexia, abdominal pain, bone pain, headache, vomiting, pain in extremity, sickle cell anemia with crisis, back pain, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, arthralgia, oropharyngeal pain, nasopharyngitis, neutrophil count decreased, cough and nausea.</paragraph>
                        <paragraph>The table below lists the adverse reactions (irrespective of a causal assessment; adverse events) of interest that occurred in patients treated with FERRIPROX in clinical trials in subjects with sickle cell disease or other anemias.</paragraph>
                        <table>
                           <caption>Table 8:
         
    Adverse reactions occurring in ≥5% of FERRIPROX-treated patients with sickle cell disease or other anemias</caption>
                           <col width="263"/>
                           <col width="129"/>
                           <col width="129"/>
                           <tbody>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">Body System </content>
                                    <content styleCode="bold">
                                       <br/>
            Adverse Reaction</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">FERRIPROX (N=152)</content>
                                    <br/>
                                    <content styleCode="bold">% Patients</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">DEFEROXAMINE (N=76)</content>
                                    <br/>
                                    <content styleCode="bold">% Patients</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">BLOOD AND LYMPHATIC SYSTEM DISORDERS</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Sickle cell anemia with crisis</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">17</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">13</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">GASTROINTESTINAL DISORDERS</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Abdominal pain*</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">26</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">13</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Vomiting</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">19</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">11</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Nausea</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">7</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">9</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Diarrhea</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">8</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Pyrexia</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">28</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">33</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Pain</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">INFECTIONS AND INFESTATIONS</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Nasopharyngitis </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">9</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">12</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Upper respiratory tract infection</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">5</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">3</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">INVESTIGATIONS</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Alanine aminotransferase increased</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">12</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Aspartate aminotransferase increased</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">11</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">0</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Neutrophil count decreased</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">8</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">4</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Bone pain</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">25</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">34</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Pain in extremity</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">18</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">15</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Back pain</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">13</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">18</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Arthralgia</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">8</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">NERVOUS SYSTEM DISORDERS</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Headache</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">20</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">13</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">
                                    <content styleCode="bold">RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Toprule Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Oropharyngeal pain</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">10</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">15</td>
                              </tr>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule Lrule Rrule">    Cough</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">8</td>
                                 <td align="center" styleCode=" Toprule Lrule Rrule">15</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*Grouped term</paragraph>
                        <paragraph>Clinically relevant adverse reactions in &lt;5% of patients include neutropenia and agranulocytosis. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>FERRIPROX has been studied in 86 pediatric patients with sickle cell disease or other anemias. Pediatric patients (&lt;17 years) had an increase in the following adverse reactions as compared to adults: abdominal pain, neutrophil count decreased, bone pain and oropharyngeal pain.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1ddddf52-1507-4ce0-9a06-de41c1ae73a6">
                     <id root="36b2354e-0640-4b06-85ba-775c0cc50739"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2</content>
                        <content styleCode="bold">
		     
	Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following additional adverse reactions have been reported in patients receiving FERRIPROX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood and lymphatic system disorders:</content> thrombocytosis, pancytopenia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac disorders:</content> atrial fibrillation, cardiac failure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Congenital, familial and genetic disorders: </content>hypospadias.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye disorders:</content> diplopia, papilledema, retinal toxicity.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal disorders:</content> enterocolitis, rectal hemorrhage, gastric ulcer, pancreatitis, parotid gland enlargement.</paragraph>
                        <paragraph>
                           <content styleCode="italics">General disorders and administration site conditions:</content> chills, edema peripheral, multi-organ failure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary disorders:</content>
                           <content styleCode="bold"> </content>jaundice, hepatomegaly.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders:</content>
                           <content styleCode="bold"> </content>anaphylactic shock, hypersensitivity.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Infections and infestations:</content> cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content> blood bilirubin increased, blood creatinine phosphokinase increased.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and nutrition disorders:</content> metabolic acidosis, dehydration.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal and connective tissue disorders:</content> myositis, chondropathy, trismus.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders:</content> cerebellar syndrome, cerebral hemorrhage, convulsion, gait disturbance, intracranial pressure increased, psychomotor skills impaired, pyramidal tract syndrome, somnolence.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric disorders:</content> bruxism, depression, obsessive-compulsive disorder.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal disorders:</content>
                           <content styleCode="bold"> </content>glycosuria, hemoglobinuria.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, thoracic and mediastinal disorders: </content>acute respiratory distress syndrome, epistaxis, hemoptysis, pulmonary embolism.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin, subcutaneous tissue disorders:</content> hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schönlein purpura.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular disorders:</content>
                           <content styleCode="bold"> </content>hypotension, hypertension.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_96f4752e-09e9-456f-a2ad-ea024f897ab9">
               <id root="89ccaf68-4e2a-447e-86d6-8fc8dbb361b8"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7</content>
                  <content styleCode="bold">
		     
	DRUG INTERACTIONS</content>
               </title>
               <text/>
               <effectiveTime value="20230701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Drugs Associated with Neutropenia or Agranulocytosis: Avoid co-administration. If co-administration is unavoidable, closely monitor the absolute neutrophil count. (<linkHtml href="#LINK_7cf733ad-0214-43d8-8adf-c3c3cd3fbf17">7.1</linkHtml>)<br/>
                           </item>
                           <item>UGT1A6 Inhibitors: Avoid co-administration. (<linkHtml href="#LINK_243d97dc-d02d-4072-97ab-30231a286638">7.2</linkHtml>)<br/>
                           </item>
                           <item>Polyvalent Cations: Allow at least a 4-hour interval between administration of FERRIPROX and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc). (<linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>, <linkHtml href="#LINK_243d97dc-d02d-4072-97ab-30231a286638">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_7cf733ad-0214-43d8-8adf-c3c3cd3fbf17">
                     <id root="bb054634-a2b7-4f97-9b3c-bd2459c5f03a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1</content>
                        <content styleCode="bold">
		     
	Drugs </content>
                        <content styleCode="bold">A</content>
                        <content styleCode="bold">ssociated with </content>
                        <content styleCode="bold">N</content>
                        <content styleCode="bold">eutropenia or </content>
                        <content styleCode="bold">A</content>
                        <content styleCode="bold">granulocytosis</content>
                     </title>
                     <text>
                        <paragraph>Avoid co-administration of FERRIPROX with other drugs known to be associated with neutropenia or agranulocytosis. If co-administration is unavoidable, closely monitor the absolute neutrophil count <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">Warnings and Precautions </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_243d97dc-d02d-4072-97ab-30231a286638">
                     <id root="b9443b7e-02a1-4c4b-9268-c69cb32f4ea3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2</content>
		     
	<content styleCode="bold">Effect of Other Drugs on FERRIPROX </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">UDP-Glucuronosyltransferases (UGT)</content>
                        </paragraph>
                        <paragraph>Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">, Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_fea5eb86-d687-484c-8e48-fd013c0d0d17">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">), Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_372a6d7c-ec99-445b-9366-b5ac496e5db0">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Polyvalent Cations</content>
                        </paragraph>
                        <paragraph>Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between FERRIPROX and other medications (e.g., antacids), or supplements containing these polyvalent cations <content styleCode="italics">[see</content>
                           <content styleCode="italics"> Dosage and Administration</content>
                           <content styleCode="italics"> </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_990c1c42-cf60-46a1-8bb7-bd3d1ce9244c">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c9756db3-e041-40ce-acd8-cce10426c997">
               <id root="84d5dae1-004f-4b01-b9c9-cbe4813f8066"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
                  <content styleCode="bold">
		     
	USE IN SPECIFIC POPULATION</content>
                  <content styleCode="bold">S</content>
               </title>
               <text/>
               <effectiveTime value="20230701"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Lactation: Advise not to breastfeed. (<linkHtml href="#LINK_b341669b-9cfa-419b-8e5f-7e1c7f0d5af1">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_c7ee98dc-4a70-4f68-8649-e46975094440">
                     <id root="8d426b68-c3df-454f-88e6-965bc9046a84"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1</content>
                        <content styleCode="bold">
		     
	Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>In animal reproduction studies, oral administration of deferiprone to pregnant rats and rabbits during organogenesis at doses 33% and 49%, respectively, of the maximum recommended human dose (MRHD) resulted in structural abnormalities, embryo-fetal mortality and alterations to growth <content styleCode="italics">(see Data)</content>. The limited available data from deferiprone use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage. Based on evidence and developmental toxicity in animal studies, FERRIPROX can cause fetal harm when administered to a pregnant woman. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes<content styleCode="italics">.</content> In the U.S. general population, the estimated background risk of major birth defects and of miscarriage is 2-4% and 15-20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human </content>
                           <content styleCode="italics">Data</content>
                        </paragraph>
                        <paragraph>Post-marketing data available from 39 pregnancies of deferiprone-treated patients and 10 pregnancies of partners of deferiprone-treated patients are as follows:</paragraph>
                        <paragraph>Of the 39 pregnancies in deferiprone-treated patients, 23 resulted in healthy newborns, 6 ended in spontaneous abortion, 9 had unknown outcomes, and 1 infant was born with anal atresia, nephroptosis, ventricular septal defect, hemivertebra and urethral fistula.</paragraph>
                        <paragraph>Of the 10 pregnancies in partners of deferiprone-treated patients, 5 resulted in healthy newborns, 1 resulted in a healthy newborn with slight hypospadias, 1 was electively terminated, 1 resulted in the intrauterine death of twins, and 2 had unknown outcomes.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>During organogenesis, pregnant rats and rabbits received deferiprone at oral doses of 0, 30, 80 or 200 mg/kg/day, and 0, 10, 50, or 150 mg/kg/day, respectively. The daily dose was administered as two equal divided doses approximately 7 hours apart. Doses of 200 mg/kg/day in rats and 150 mg/kg/day in rabbits, approximately 33% and 49% of the MRHD, respectively, resulted in increased post-implantation loss and reduced fetal weights in the presence of maternal toxicity (reduced maternal body weight and body weight gain in both rats and rabbits; abnormal large placenta at low incidence in rats). The 200 mg/kg/day dose in rats resulted in external, visceral and skeletal fetal malformations such as cranial malformations, cleft palate, limb malrotation, anal atresia, internal hydrocephaly, anophthalmia and fused bones. The dose of 150 mg/kg/day in rabbits resulted in external fetal malformations (partially opened eyes) and minor blood vessel and skeletal variations.</paragraph>
                        <paragraph>In rats, malformations including micrognathia and persistent ductus arteriosus could be observed in the absence of maternal toxicity at doses equal to or greater than 30 and 80 mg/kg/day, approximately 5% and 13% of the MHRD, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b341669b-9cfa-419b-8e5f-7e1c7f0d5af1">
                     <id root="a0731b99-886e-4a32-8154-92fcec9b5000"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2</content>
                        <content styleCode="bold">
		     
	Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of deferiprone in human milk, the effects on the breastfed child, or the effects on milk production.</paragraph>
                        <paragraph>Because of the potential for serious adverse reactions in the breastfed child, including the potential for tumorigenicity shown for deferiprone in animal studies, advise patients that breastfeeding is not recommended during treatment with FERRIPROX, and for at least 2 weeks after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_74dcb2ac-90d7-495b-8ede-fb5379dbed7e">
                     <id root="f63c40c9-b066-413a-98a9-39bdaa57c71f"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>
                        <content styleCode="bold">8.3</content>
                        <content styleCode="bold">
		     
	Females and Males of Reproductive Potential</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Pregnancy testing is recommended for females of reproductive potential prior to initiating FERRIPROX.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>FERRIPROX can cause embryo-fetal harm when administered to a pregnant woman <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_c7ee98dc-4a70-4f68-8649-e46975094440">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Advise female patients of reproductive potential to use effective contraception during treatment with FERRIPROX and for at least 6 months after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with FERRIPROX and for at least 3 months after the last dose <content styleCode="italics">[</content>
                           <content styleCode="italics">see Nonclinical Toxicology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_4b36de80-fd95-4918-8eb6-00cf19ecc5c0">13.1</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ce4ecfe4-72c8-4fb7-8f19-3fc1727ea81d">
                     <id root="75a04366-a726-4249-86aa-4cd2b96dbf51"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4</content>
                        <content styleCode="bold">
		     
	Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>The safety and effectiveness of FERRIPROX for the treatment of transfusional iron overload due to thalassemia syndromes have been established in pediatric patients 8 years of age and older. Use of FERRIPROX for this indication is supported by evidence of efficacy from clinical trials in adult patients with thalassemia and evidence of safety in pediatric patients with sickle cell disease.</paragraph>
                        <paragraph>The safety and effectiveness of FERRIPROX for the treatment of transfusional iron overload due to sickle cell disease or other anemias have been established in 86 pediatric patients 3 to 16 years of age, among the 152 patients treated with FERRIPROX Tablets or Oral Solution in an adequate and well-controlled study <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_fea5eb86-d687-484c-8e48-fd013c0d0d17">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">) and Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_398e829a-3c5e-4695-961a-bb76e4f20664">14.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. The study included 56 patients 3 to &lt;12 years of age and 30 patients 12 to 16 years of age.  Seventy-six percent of these patients had sickle cell disease. The recommended starting dose and dose-modifications are the same for children and adults <content styleCode="italics">[see Indications and Usage (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_dde09d7d-ba4c-45fa-9021-9432489e719f">1</linkHtml>
                           </content>
                           <content styleCode="italics">), Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_29e05553-1069-41b4-9417-20fee276aa23">2.1</linkHtml>
                           </content>
                           <content styleCode="italics">), and Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_864f800c-3c6e-4a91-8d3b-f59679a14746">14</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>Fourteen patients with spherocytosis (including hereditary) (ages 3-15), two patients with pyruvate kinase deficiency (ages 4 and 6), two patients with dyserythropoietic anemia (ages 10-12) and two patients with hemolytic anemia (ages 8 and 10 years old) were treated with FERRIPROX in the clinical trial, LA38-0411.</paragraph>
                        <paragraph>A US registry established from December 2011 through December 2019, contains 125 patients from 4 to &lt; 17 years old who have received FERRIPROX and have sickle cell disease. The adverse reactions, including agranulocytosis, seen in the 8 year period of the registry are similar to those seen in the most recent clinical studies.</paragraph>
                        <paragraph>Safety and effectiveness of FERRIPROX Tablets have not been established in pediatric patients with chronic iron overload due to blood transfusions who are less than 8 years of age.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6cc8d7ab-88f5-4396-b349-b08d7e0de861">
                     <id root="0c260d3e-5cc4-43f0-9c61-bdeb7ba1b1a2"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5</content>
                        <content styleCode="bold">
		     
	Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Clinical studies of deferiprone did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_363f407b-d141-4df0-85bc-968164a9accb">
               <id root="7ab0b349-ac75-47f7-8662-c422a7a1e6a3"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10</content>
                  <content styleCode="bold">
		     
	OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>No cases of acute overdose have been reported. There is no specific antidote to FERRIPROX overdose.</paragraph>
                  <paragraph>Neurological disorders such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, hand movements and axial hypotonia have been observed in children treated with 2.5 to 3 times the recommended dose for more than one year. The neurological disorders progressively regressed after deferiprone discontinuation.</paragraph>
               </text>
               <effectiveTime value="20230701"/>
            </section>
         </component>
         <component>
            <section ID="LINK_a010cb15-def8-4dd1-8b5e-c5f8cb3cd7c7">
               <id root="755b32c2-4c53-4452-9898-d0ec92cafcb0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
                  <content styleCode="bold">
		     
	DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>FERRIPROX Tablets (deferiprone) contain 1,000 mg or 500 mg deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a synthetic, orally active, iron-chelating agent. The molecular formula for deferiprone is C<sub>7</sub>H<sub>9</sub>NO<sub>2</sub> and its molecular weight is 139.15 g/mol. Deferiprone has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Deferiprone is a white to pinkish-white powder. It is sparingly soluble in deionized water (14.3 mg/mL) and has a melting point range of 272 °C - 278 °C.</paragraph>
                  <paragraph>
                     <content styleCode="underline">FERRIPROX Tablets</content>
                     <content styleCode="underline"> </content>
                     <content styleCode="underline">(</content>
                     <content styleCode="underline">twice a day)</content>
                     <content styleCode="underline">, 1,000 mg</content>
                  </paragraph>
                  <paragraph>White to off-white, capsule-shaped tablets, and imprinted with “FPX” score “DR” on one side and “APO” score “1000” on the other. The tablets can be broken in half along the score line. Each tablet contains 1,000 mg deferiprone and the following inactive ingredients: Tablet core - hypromellose acetate succinate, magnesium oxide, colloidal silicon dioxide and magnesium stearate; Coating - triethyl citrate, talc, titanium dioxide, and methacrylic acid and ethyl acrylate copolymer. </paragraph>
                  <paragraph>
                     <content styleCode="underline">FERRIPROX</content>
                     <content styleCode="underline"> </content>
                     <content styleCode="underline">T</content>
                     <content styleCode="underline">ablets</content>
                     <content styleCode="underline"> (three times </content>
                     <content styleCode="underline">a </content>
                     <content styleCode="underline">day)</content>
                     <content styleCode="underline">,</content>
                     <content styleCode="underline"> 1,000 mg</content>
                  </paragraph>
                  <paragraph>White to off-white, capsule-shaped tablets, and imprinted with “APO” score “1000” on one side and plain on the other. The tablets can be broken in half along the score line. Each tablet contains 1,000 mg deferiprone and the following inactive ingredients: Tablet core - methylcellulose, crospovidone, and magnesium stearate; Coating - hypromellose, hydroxypropyl cellulose, macrogol, and titanium dioxide.</paragraph>
                  <paragraph>
                     <content styleCode="underline">FERRIPROX Tablets</content>
                     <content styleCode="underline">, 500 mg</content>
                  </paragraph>
                  <paragraph>White to off-white, capsule-shaped tablets, and imprinted with “APO” score “500” on one side and plain on the other. The tablets can be broken in half along the score line. Each tablet contains 500 mg deferiprone and the following inactive ingredients: Tablet core - microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide; Coating - hypromellose, polyethylene glycol, titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20230701"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>structural formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ferriprox-tablets-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_daf178d8-bc14-4bb8-96ef-9b3cbbe431eb">
               <id root="fb0606dc-f393-43f8-a0be-f959772dbd46"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
                  <content styleCode="bold">
		     
	CLINICAL PHARMACOLOGY</content>
               </title>
               <text/>
               <effectiveTime value="20230701"/>
               <component>
                  <section ID="LINK_d4a90eab-0bc6-4dad-9c3e-383ff63f1bdf">
                     <id root="ed258e5f-f7d1-41a4-9bb1-7ac8b9e28592"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
                        <content styleCode="bold">
		     
	Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Deferiprone is a chelating agent with an affinity for ferric ions (iron III). Deferiprone binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable at physiological pH. </paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_eeea34f6-f9dd-4b8a-9a1a-5b4b32c04fbc">
                     <id root="20a1137a-0c83-4acf-b5fa-98332d65a386"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2</content>
                        <content styleCode="bold">
		     
	Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>No clinical studies were performed to assess the relationship between the dose of deferiprone and the amount of iron eliminated from the body.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At the maximum approved recommended dose, deferiprone does not prolong the QT interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_372a6d7c-ec99-445b-9366-b5ac496e5db0">
                     <id root="d92101a9-d7cf-41f1-9afc-4f1ac927ec1f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3</content>
                        <content styleCode="bold">
		     
	Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">FERRIPROX Tablets (twice a day), 1,000 mg</content>
                        </paragraph>
                        <paragraph>In healthy subjects, the mean ± SD C<sub>max</sub> of deferiprone in serum was 6 ± 2 mcg/mL, and the mean ± SD AUC was 28 ± 7 mcg∙h/mL following oral administration of a 1,000 mg dose of FERRIPROX Tablets (twice a day) with food.</paragraph>
                        <paragraph>Absorption</paragraph>
                        <paragraph>Peak serum concentrations of deferiprone occur approximately 2 hours after a single dose of FERRIPROX Tablets (twice a day) in fasted healthy subjects. </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Effect of Food</content>
                           </content>
                        </paragraph>
                        <paragraph>Following the administration of FERRIPROX Tablets (twice a day) to healthy volunteers, the C<sub>max</sub> and the AUC of deferiprone remain unchanged after a high-fat meal (approximately 1,000 calories, 53% fat, 33% carbohydrates, and 14% protein) compared to fasted conditions.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Effect of Alcohol</content>
                           </content>
                        </paragraph>
                        <paragraph>At 40% (v/v) alcohol concentration <content styleCode="italics">in vitro</content> dissolution studies, there was 88% release of deferiprone from a 1,000 mg FERRIPROX tablet (twice a day) within two hours compared to 4% release of deferiprone within 2 hours in the absence of alcohol.</paragraph>
                        <paragraph>Distribution</paragraph>
                        <paragraph>The apparent mean ± SD volume of distribution (V/F) of deferiprone was 97 ± 28 L following oral administration of a 1,000 mg dose of FERRIPROX Tablets (twice a day) with food.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The mean ± SD elimination half-life of deferiprone is 1.8 ± 0.3 hours following the administration of FERRIPROX Tablets (twice a day).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Deferiprone is metabolized primarily by UGT1A6. The major metabolite of deferiprone is the 3-<content styleCode="italics">O</content>-glucuronide, which lacks iron- binding capability.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following oral administration, 75% to 90% of the administered dose was recovered in urine (primarily as metabolite) in the first 24 hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">FERRIPROX Tablets</content>
                           <content styleCode="underline"> (three times a day)</content>
                           <content styleCode="underline">, </content>
                           <content styleCode="underline">1,000 mg </content>
                           <content styleCode="underline">and </content>
                           <content styleCode="underline">500 mg</content>
                        </paragraph>
                        <paragraph>The mean C<sub>max</sub> and AUC of deferiprone was 20 mcg/mL and 50 mcg∙h/mL, respectively, in healthy subjects. The dose proportionality of deferiprone over the approved recommended dosage range is unknown.</paragraph>
                        <paragraph>Absorption</paragraph>
                        <paragraph>Deferiprone appeared in the blood within 5 to 10 minutes after oral administration. Peak serum concentration of deferiprone was reached approximately 1 to 2 hours after a single dose. </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Effect of Food</content>
                           </content>
                        </paragraph>
                        <paragraph>No clinically significant differences in the pharmacokinetics of deferiprone were observed following administration with food.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The elimination half-life of deferiprone is approximately 2 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Deferiprone is metabolized primarily by UGT1A6. The major metabolite of deferiprone is the 3-<content styleCode="italics">O</content>-glucuronide, which lacks iron binding capability.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following oral administration, 75% to 90% of the administered dose was recovered in urine (primarily as metabolite) in the first 24 hours.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                     <component>
                        <section ID="LINK_a1e0604a-0f2a-4e0d-aae8-40e29dc60c39">
                           <id root="12134040-8616-4b36-a5bc-fc56b009f7fb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Specific P</content>
                              <content styleCode="underline">opulations</content>
                           </title>
                           <text>
                              <paragraph>No clinically significant differences in the pharmacokinetics of deferiprone were observed based on sex, race/ethnicity, body weight, mild to severe (eGFR 15 to 89 mL/min/1.73 m<sup>2</sup>) renal impairment, or mild (Child Pugh Class A) to moderate (Child Pugh Class B) hepatic impairment. The effect of age, including geriatric or pediatric populations, end stage renal disease or severe (Child Pugh Class C) hepatic impairment on the pharmacokinetics of deferiprone is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20230701"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_b362de95-b5bf-4643-bfa2-149bfb48face">
                           <id root="39d708c1-c6c5-46a6-8d4e-0928c2bf1a1a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Drug Interaction</content>
                              <content styleCode="underline"> Studie</content>
                              <content styleCode="underline">s</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">In Vitro Studies</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">UGTIA6 Inhibitors</content>
                                 <content styleCode="italics">:</content> Phenylbutazone (UGT1A6 inhibitor) decreased glucuronidation of deferiprone by up to 78%.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Polyvalent Cations:</content> Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc).</paragraph>
                           </text>
                           <effectiveTime value="20230701"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d29ebedc-c13c-4435-9df4-86b9eb861e65">
               <id root="f068fb16-1cf9-4c77-ac93-f70cc2868466"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13</content>
		     
	<content styleCode="bold">NONCLINICAL TOXICOLOGY</content>
               </title>
               <text/>
               <effectiveTime value="20230701"/>
               <component>
                  <section ID="LINK_4b36de80-fd95-4918-8eb6-00cf19ecc5c0">
                     <id root="eefba197-9f45-4489-be1f-0ed98008c918"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">13.1</content>
                        <content styleCode="bold">
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with deferiprone. However, in view of the genotoxicity results, and the findings of mammary gland hyperplasia and mammary gland tumors in rats treated with deferiprone in the 52-week toxicology study, tumor formation in carcinogenicity studies must be regarded as likely.</paragraph>
                        <paragraph>Deferiprone was positive in a mouse lymphoma cell assay <content styleCode="italics">in vitro</content>. Deferiprone was clastogenic in an <content styleCode="italics">in vitro</content> chromosomal aberration test in mice and in a chromosomal aberration test in Chinese Hamster Ovary cells. Deferiprone given orally or intraperitoneally was clastogenic in a bone marrow micronucleus assay in non-iron-loaded mice. A micronucleus test was also positive when mice predosed with iron dextran were treated with deferiprone. Deferiprone was not mutagenic in the Ames bacterial reverse mutation test.</paragraph>
                        <paragraph>A fertility and early embryonic development study of deferiprone was conducted in rats. Sperm counts, motility and morphology were unaffected by treatment with deferiprone. There were no effects observed on male or female fertility or reproductive function at the highest dose which was 25% of the MRHD.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_864f800c-3c6e-4a91-8d3b-f59679a14746">
               <id root="67058de5-96eb-4972-9cd3-3a71b235d24f"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
		     
	<content styleCode="bold">CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>FERRIPROX Tablets (twice a day) were evaluated in trials in healthy subjects. FERRIPROX Tablets (twice a day) contain deferiprone, the same active ingredient as FERRIPROX Tablets and FERRIPROX Oral Solution. The following information is based on studies with FERRIPROX Tablets (deferiprone) (three times a day) and FERRIPROX Oral Solution (deferiprone).</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="LINK_fc89c9f2-16e4-4e81-aadf-79e4a7834d61">
                     <id root="bbd82625-33bb-4139-b1e2-374e8737bd90"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.1</content>
		     
	<content styleCode="bold">Transfusional Iron Overload</content>
                        <content styleCode="bold"> in Patients with Thalassemia Syndromes</content>
                     </title>
                     <text>
                        <paragraph>In a prospective, planned, pooled analysis of patients with thalassemia syndromes from several studies, the efficacy of deferiprone was assessed in transfusion-dependent iron overload patients in whom previous iron chelation therapy had failed or was considered inadequate due to poor tolerance. The main criterion for chelation failure was serum ferritin &gt; 2,500 mcg/L before treatment with deferiprone. Deferiprone therapy (35-99 mg/kg/day) was considered successful in individual patients who experienced a ≥ 20% decline in serum ferritin within one year of starting therapy.</paragraph>
                        <paragraph>Data from a total of 236 patients were analyzed. Of the 224 patients with thalassemia who received deferiprone monotherapy and were eligible for serum ferritin analysis, 105 (47%) were male and 119 (53%) were female. The mean age of these patients was 18.2 years (range 2 to 62; 91 patients were &lt;17).</paragraph>
                        <paragraph>For the patients in the analysis, the endpoint of at least a 20% reduction in serum ferritin was met in 50% (of 236 subjects), with a 95% confidence interval of 43% to 57%.</paragraph>
                        <paragraph>A small number of patients with thalassemia and iron overload were assessed by measuring the change in the number of milliseconds (ms) in the cardiac MRI T2* value before and after treatment with deferiprone for one year. There was an increase in cardiac MRI T2* from a mean at baseline of 11.8 ± 4.9 ms to a mean of 15.1 ± 7.0 ms after approximately one year of treatment. The clinical significance of this observation is not known.</paragraph>
                     </text>
                     <effectiveTime value="20230701"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_398e829a-3c5e-4695-961a-bb76e4f20664">
                     <id root="3d4cc948-80b9-440f-bcbc-d5c2f5e5072b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.2</content>
     
<content styleCode="bold">Transfusional Iron Overload in Patients with Sickle Cell Disease </content>
                        <content styleCode="bold">and </content>
                        <content styleCode="bold">other </content>
                        <content styleCode="bold">A</content>
                        <content styleCode="bold">nemias</content>
                     </title>
                     <text>
                        <paragraph>Study LA38-0411, an actively-controlled non-inferiority study compared the efficacy of FERRIPROX to that of deferoxamine in patients with sickle cell disease and other transfusion-dependent anemias by evaluating liver iron concentration (LIC). The efficacy of FERRIPROX was established based upon the change in LIC from baseline after 12 months of FERRIPROX (75 or 99 mg/kg/day) compared to deferoxamine (20 or 40 mg/kg (pediatric patients); 40 or 50 mg/kg (adult patients)). Patient enrollment was stopped following an interim analysis. After adjusting for the type I (alpha) error, the non-inferiority criterion was established as the upper limit of the 96.01% confidence interval for the difference between treatments being ≤2 mg/g dry weight (dw).</paragraph>
                        <paragraph>Data from 185 patients (122 on FERRIPROX and 63 on deferoxamine) were available. Among the 122 FERRIPROX treated patients, the mean age was 15.9 years (range 3-46); 57.4% were male; 75.4% were White, 17.2% were Black and 7.4% were Multi-racial; 85% were diagnosed with Sickle Cell Disease and 15% with other anemias. Over 12 months, the Least Squares estimate of mean decrease from baseline in LIC was 4.13 ± 0.50 mg/g dw for FERRIPROX and 4.38 ± 0.59 mg/g dw for deferoxamine, and the non-inferiority criterion was met.</paragraph>
                        <paragraph>Upon completion of the first year of therapy in the non inferiority study, 89 patients from the FERRIPROX group opted to continue with treatment and 45 from the deferoxamine group opted to switch to ferriprox treatment. This group continued for up to an additional 2 years. LIC continued to decrease over time, with the mean value dropping from 14.93 mg/g dw at baseline to 12.30 mg/g dw after one year of treatment, to 11.19 mg/g dw after two years of treatment, and to 10.45 mg/g dw after three years of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3cff725c-0c96-4359-b9f1-3cdce8e168e7">
               <id root="18597afd-423a-40f7-8396-9f6b6c402bb6"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16</content>
                  <content styleCode="bold">
		     
	HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">FERRIPROX Tablets</content>
                     <content styleCode="underline"> (</content>
                     <content styleCode="underline">twice a day)</content>
                     <content styleCode="underline">, 1,000 mg</content>
                  </paragraph>
                  <paragraph>FERRIPROX<sup>®</sup> Tablets (deferiprone) (twice a day) are white to off-white capsule-shaped, beveled edge, biconvex coated tablets, and have a functional score engraved “FPX” bisect “DR” on one side, “APO” bisect “1000” on the other. They are supplied in child-resistant blister packs or HDPE bottles.</paragraph>
                  <paragraph>1,000 mg tablets, carton of 5 x 10-count blister packs NDC 10122-104-01</paragraph>
                  <paragraph>1,000 mg tablets, bottle of 50 tablets NDC 10122-104-05</paragraph>
                  <paragraph>1,000 mg tablets, bottle of 500 tablets NDC 10122-104-50</paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="underline">F</content>
                     <content styleCode="underline">ERRIPROX </content>
                     <content styleCode="underline">T</content>
                     <content styleCode="underline">ablets</content>
                     <content styleCode="underline"> (three times </content>
                     <content styleCode="underline">a </content>
                     <content styleCode="underline">day)</content>
                     <content styleCode="underline">, 1,000 mg</content>
                  </paragraph>
                  <paragraph>FERRIPROX<sup>®</sup> Tablets (deferiprone) (three times a day) are white to off-white capsule-shaped tablets, film-coated, and have a functional score imprinted with “APO” score “1000” on one side and are plain on the other. They are provided in HDPE bottles.</paragraph>
                  <paragraph>1,000 mg film-coated tablets, 50 tablets NDC 10122-103-05</paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep the bottle tightly closed to protect from moisture.</paragraph>
                  <paragraph>
                     <content styleCode="underline">FERRIPROX Tablets</content>
                     <content styleCode="underline">, 500 mg</content>
                  </paragraph>
                  <paragraph>FERRIPROX<sup>®</sup> Tablets (deferiprone) are white to off-white capsule-shaped tablets, film-coated, and have a functional score imprinted with “APO” score “500” on one side and are plain on the other. They are provided in HDPE bottles.</paragraph>
                  <paragraph>500 mg film-coated tablets, 100 tablets NDC 10122-100-10</paragraph>
                  <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20230701"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b5c5cb14-03b0-4d45-b444-b02730680de1">
               <id root="883f051f-9805-4076-adcb-12103cb7b485"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
                  <content styleCode="bold">
     
PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide)</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Instruct patients and their caregivers to store FERRIPROX at 68°F to 77°F (20°C to 25°C); excursions permitted to 59°F to 86°F (15°C to 30°C) [see USP Controlled Room Temperature].</item>
                     <item>
                        <content styleCode="underline">F</content>
                        <content styleCode="underline">ERRIPROX </content>
                        <content styleCode="underline">Tablets</content>
                        <content styleCode="underline"> (</content>
                        <content styleCode="underline">t</content>
                        <content styleCode="underline">wice</content>
                        <content styleCode="underline"> a </content>
                        <content styleCode="underline">day</content>
                        <content styleCode="underline">), 1,000 mg</content>
                        <content styleCode="underline">:</content>
                        <br/>
    Advise patients to take the first dose of FERRIPROX Tablets (twice a day) in the morning and the second in the evening.<br/>
    Advise patients to take FERRIPROX Tablets (twice a day) with food to reduce the risk of nausea and vomiting.<br/>
    Advise patients to avoid alcohol while taking FERRIPROX Tablets (twice a day). Consumption of alcohol while taking FERRIPROX Tablets (twice a day) may result in more rapid release of deferiprone.</item>
                     <item>
                        <content styleCode="underline">F</content>
                        <content styleCode="underline">ERRIPROX </content>
                        <content styleCode="underline">T</content>
                        <content styleCode="underline">ablets</content>
                        <content styleCode="underline"> (three times </content>
                        <content styleCode="underline">a </content>
                        <content styleCode="underline">day)</content>
                        <content styleCode="underline">, 1,000 mg</content>
                        <content styleCode="underline">:</content>
                        <br/>
    Store in the originally supplied bottle, closed tightly to protect from moisture.<br/>
    Advise patients to take the first dose of FERRIPROX in the morning, the second dose at midday, and the third dose in the evening. Clinical experience suggests that taking FERRIPROX with meals may reduce nausea.</item>
                     <item>
                        <content styleCode="underline">F</content>
                        <content styleCode="underline">ERRIPROX </content>
                        <content styleCode="underline">Tablets</content>
                        <content styleCode="underline">, 500 mg</content>
                        <content styleCode="underline">:</content>
                        <br/>
    Store in the originally supplied bottle, closed tightly to protect from moisture.<br/>
    Advise patients to take the first dose of FERRIPROX in the morning, the second dose at midday, and the third dose in the evening. Clinical experience suggests that taking FERRIPROX with meals may reduce nausea.</item>
                     <item>If a dose of this medicine has been missed, take it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to the regular dosing schedule. Do not catch-up or double doses.</item>
                     <item>Inform patients of the risks of developing agranulocytosis and the need for regular blood testing before and during their treatment to monitor for decreases in their ANC. Instruct them to immediately interrupt therapy and report to their physician if they experience any symptoms of infection such as fever, sore throat or flu-like symptoms <content styleCode="italics">[see </content>
                        <content styleCode="italics">Dosage and Administration (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_29e05553-1069-41b4-9417-20fee276aa23">2.1</linkHtml>
                        </content>
                        <content styleCode="italics">) and </content>
                        <content styleCode="italics">Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_e34a59f4-e6ed-4cb9-8491-fe5a5ef675b4">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content> in order to check their ANC within 24 hours. Advise them if they are unable to reach their physician, seek care from another provider so as not to delay medical care.</item>
                     <item>Inform patients of the risk of abnormal liver transaminases and the need for regular blood testing before and during their treatment to monitor for increases in ALT <content styleCode="italics">[see </content>
                        <content styleCode="italics">Dosage and Administration (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_29e05553-1069-41b4-9417-20fee276aa23">2.1</linkHtml>
                        </content>
                        <content styleCode="italics">) and </content>
                        <content styleCode="italics">Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_5c74c56f-0e35-4103-8e44-45fb736c46c8">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>. </item>
                     <item>Inform patients of the risk of zinc deficiency and the need for regular blood testing before and during their treatment to monitor for reductions in zinc <content styleCode="italics">[see </content>
                        <content styleCode="italics">Dosage and Administration (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_29e05553-1069-41b4-9417-20fee276aa23">2.1</linkHtml>
                        </content>
                        <content styleCode="italics">) and </content>
                        <content styleCode="italics">Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_3cb3a25c-be0b-4e91-8624-68d4e46eae8e">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>.</item>
                     <item>Advise patients to contact their physician in the event of overdose.</item>
                     <item>Inform patients that their urine might show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. This is a very common sign of the desired effect, and it is not harmful.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal toxicity</content>
                  </paragraph>
                  <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_f2b9c274-313f-4d26-bb21-270fbb116b0a">5.4</linkHtml>
                     </content>
                     <content styleCode="italics">) and Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_c7ee98dc-4a70-4f68-8649-e46975094440">8.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. Advise female patients of reproductive potential to use effective contraception during treatment with FERRIPROX and for at least six months after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_c7ee98dc-4a70-4f68-8649-e46975094440">8.1</linkHtml>
                     </content>
                     <content styleCode="italics">, </content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_74dcb2ac-90d7-495b-8ede-fb5379dbed7e">8.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. Advise males with female partners of reproductive potential to use effective contraception during treatment with FERRIPROX and for at least three months after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_74dcb2ac-90d7-495b-8ede-fb5379dbed7e">8.3</linkHtml>
                     </content>
                     <content styleCode="italics">) and Nonclinical Toxicology (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_4b36de80-fd95-4918-8eb6-00cf19ecc5c0">13.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise females not to breastfeed during treatment with FERRIPROX and for at least 2 weeks after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_b341669b-9cfa-419b-8e5f-7e1c7f0d5af1">8.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>Distributed by Chiesi USA, Inc., Cary, NC 27518. Manufactured by Apotex Inc., Toronto, Ontario, Canada, M9L 1T9.</paragraph>
                  <paragraph>US-618-s1-W</paragraph>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="LINK_128f67da-9a50-417b-aae5-703f537e6a9b">
               <id root="2f6fe3c1-ff03-4ab6-be7f-1e080495fffa"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <table>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">Medication Guide </content>
                              <br/>
                              <content styleCode="bold">FERRIPROX (Feh ri prox) Tablets</content>
                              <br/>
                              <content styleCode="bold">(deferiprone)</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">What is the most important information I should know about FERRIPROX Tablets?</content>
                              <br/>
                              <content styleCode="bold">FERRIPROX Tablets can cause serious side effects</content>, including a very low white blood cell count. One type of white blood cell that is important for fighting infections is called a neutrophil. If your neutrophil count is low (neutropenia), you may be at risk of developing a serious infection that can lead to death. Neutropenia is common with FERRIPROX Tablets and can become severe in some people. Severe neutropenia is known as agranulocytosis. If you develop agranulocytosis, you will be at risk of developing serious infections that can lead to death.<br/>Your healthcare provider will do a blood test before you start FERRIPROX Tablets and regularly during treatment to check your neutrophil count. If you develop neutropenia, your healthcare provider should check your blood counts every day until your white blood cell count improves. Your healthcare provider may temporarily stop treatment with FERRIPROX Tablets if you develop neutropenia or infection.<br/>
                              <content styleCode="bold">Stop taking FERRIPROX Tablets and call your healthcare provider or get medical help right away if you develop any of these symptoms of infection:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disk">
                                 <item>fever<br/>
                                 </item>
                                 <item>sore throat or mouth sores<br/>
                                 </item>
                                 <item>flu-like symptoms<br/>
                                 </item>
                                 <item>chills and severe shaking</item>
                              </list>
                              <content styleCode="bold">It is important for you to have your white blood cell count checked within 24 hours of developing symptoms of an infection to see if you have severe neutropenia (agranulocytosis). Do not delay getting medical care if you are unable to reach your healthcare provider.</content>
                              <br/>See <content styleCode="bold">“What are the possible side effects of FERRIPROX Tablets?”</content> for more information about side effects.</td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">What is FERRIPROX Tablets?</content>
                              <br/>FERRIPROX Tablets is a prescription medicine used to treat iron overload from blood transfusions in adults and children 8 years of age and older with:<br/>
                              <list listType="unordered" styleCode="Disk">
                                 <item>thalassemia syndromes.<br/>
                                 </item>
                                 <item>sickle cell disease or other anemias.</item>
                              </list>It is not known if FERRIPROX Tablets is safe and effective to treat iron overload due to blood transfusions:<list listType="unordered" styleCode="Disk">
                                 <item>in people with myelodysplastic syndrome or Diamond Blackfan anemia<br/>
                                 </item>
                                 <item>in children less than 8 years of age</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">Do not take FERRIPROX Tablets if you are allergic to deferiprone or any of the ingredients in FERRIPROX Tablets.</content> See the end of this Medication Guide for a complete list of ingredients in FERRIPROX Tablets.</td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">Before taking FERRIPROX Tablets, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disk">
                                 <item>have liver problems<br/>
                                 </item>
                                 <item>are pregnant or plan to become pregnant. FERRIPROX Tablets can harm your unborn baby. You should avoid becoming pregnant during treatment with FERRIPROX Tablets. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with FERRIPROX Tablets.</item>
                              </list>
                              <content styleCode="bold">Females who are able to become pregnant:</content>
                              <br/>○ Your healthcare provider should do a pregnancy test before you start treatment with FERRIPROX Tablets.<br/>○ You should use effective birth control during treatment with FERRIPROX Tablets and for at least 6 months after the last dose.<br/>
                              <content styleCode="bold">Males with female partners who are able to become pregnant:</content>
                              <br/>○ You should use effective birth control during treatment with FERRIPROX Tablets and for at least 3 months after the last dose.<br/>
                              <list listType="unordered" styleCode="Disk">
                                 <item>are breastfeeding or plan to breastfeed. It is not known if FERRIPROX Tablets passes into your breast milk. Do not breastfeed during treatment with FERRIPROX Tablets and for at least 2 weeks after the last dose.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins and herbal supplements.</td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">How should I take FERRIPROX Tablets?</content>
                              <list listType="unordered" styleCode="Disk">
                                 <item>Take FERRIPROX Tablets exactly as your healthcare provider tells you.<br/>
                                 </item>
                                 <item>Your healthcare provider will prescribe FERRIPROX Tablets based on your body weight. <br/>
                                 </item>
                                 <item>Your healthcare provider will check your body iron level during treatment with FERRIPROX Tablets and may change your dose if needed. Your healthcare provider may also change your dose of FERRIPROX Tablets if you have certain side effects. Do not change your dose of FERRIPROX Tablets unless your healthcare provider tells you to.</item>
                              </list>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">There are 3 types of FERRIPROX Tablets that are taken on different schedules. Be sure you are taking the correct tablet and ask your healthcare provider if unsure.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="3" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">FERRIPROX Tablets</content>
                              <br/>
                              <content styleCode="bold">1,000 mg Twice-a-Day</content>
                              <br/>
                              <content styleCode="bold">2 times each day with food</content>
                           </td>
                           <td align="center" colspan="3" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">FERRIPROX Tablets</content>
                              <br/>
                              <content styleCode="bold">1,000 mg</content>
                              <br/>
                              <content styleCode="bold">3 times each day</content>
                           </td>
                           <td align="center" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">FERRIPROX Tablets</content>
                              <br/>
                              <content styleCode="bold">500 mg</content>
                              <br/>
                              <content styleCode="bold">3 times each day</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" styleCode=" Lrule Rrule">Take your first dose in the morning<br/>and the second dose in the<br/>evening, about 12 hours apart.</td>
                           <td colspan="3" styleCode=" Lrule Rrule">Take your first dose in the<br/>morning, the second dose at mid<br/>day, and the third dose in the<br/>evening.</td>
                           <td styleCode=" Lrule Rrule">Take your first dose in the<br/>morning, the second dose at<br/>mid-day, and the third dose<br/>in the evening.</td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>Taking FERRIPROX Tablets with meals may help reduce nausea.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">If you must take a medicine to treat indigestion (antacid), or supplements that contain iron, aluminum, or zinc during treatment with FERRIPROX Tablets, allow at least 4 hours between taking FERRIPROX Tablets and these products.</content>
                                    <br/>
                                 </item>
                                 <item>If you take too much FERRIPROX Tablets, call your healthcare provider.<br/>
                                 </item>
                                 <item>If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and then continue with your regular schedule. Do not try to catch-up or take 2 doses at the same time to make up for a missed dose.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">What should I avoid during treatment with FERRIPROX Tablets?</content>
                              <list listType="unordered" styleCode="Disk">
                                 <item>Avoid drinking alcohol during treatment with FERRIPROX Tablets 1,000 mg (2 times a day). This may cause a faster release of the medicine.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of FERRIPROX Tablets?</content>
                              <br/>
                              <content styleCode="bold">FERRIPROX Tablets can cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">See “What is the most important information I should know about FERRIPROX Tablets?”</content>
                                    <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased liver enzyme levels in your blood.</content> Your healthcare provider should do blood tests to check your liver function before you start and then monthly during treatment with FERRIPROX Tablets. Your healthcare provider may temporarily stop treatment with FERRIPROX Tablets if you develop increased liver enzyme levels and they continue to be increased.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Decreased levels of zinc in your blood.</content> Your healthcare provider will do blood tests to check your zinc levels before you start and during treatment with FERRIPROX Tablets, and may prescribe a zinc supplement for you if your zinc levels are low.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Lrule Rrule">
                              <content styleCode="bold">The most common side effects of FERRIPROX Tablets in people with thalassemia include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>nausea<br/>
                                 </item>
                                 <item>joint paint</item>
                              </list>
                           </td>
                           <td colspan="3">
                              <list listType="unordered" styleCode="Disk">
                                 <item>vomiting<br/>
                                 </item>
                                 <item>abnormal liver function tests</item>
                              </list>
                           </td>
                           <td colspan="3" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>stomach-area (abdominal) pain<br/>
                                 </item>
                                 <item>low white blood cells</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Lrule Rrule">
                              <content styleCode="bold">The most common side effects of FERRIPROX Tablets in people with sickle cell disease or other anemias include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>fever<br/>
                                 </item>
                                 <item>headache<br/>
                                 </item>
                                 <item>sickle cell anemia with crisis<br/>
                                 </item>
                                 <item>joint pain<br/>
                                 </item>
                                 <item>low white blood cells</item>
                              </list>
                           </td>
                           <td colspan="3">
                              <list listType="unordered" styleCode="Disk">
                                 <item>stomach-area (abdominal) pain<br/>
                                 </item>
                                 <item>vomiting<br/>
                                 </item>
                                 <item>back pain<br/>
                                 </item>
                                 <item>mouth and throat pain<br/>
                                 </item>
                                 <item>cough</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>bone pain<br/>
                                 </item>
                                 <item>pain in arms or legs<br/>
                                 </item>
                                 <item>abnormal liver function tests<br/>
                                 </item>
                                 <item>common cold<br/>
                                 </item>
                                 <item>nausea</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Lrule Rrule">FERRIPROX Tablets may cause a change in urine color to reddish-brown. This is not harmful and is expected during treatment with FERRIPROX Tablets.<br/>These are not all of the possible side effects of FERRIPROX Tablets.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">How should I store FERRIPROX Tablets?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">FERRIPROX Tablets</content>
                              <br/>
                              <content styleCode="bold">1,000 mg Twice-a-Day</content>
                              <br/>
                              <content styleCode="bold">2 times each day with food</content>
                           </td>
                           <td align="center" colspan="3" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">FERRIPROX Tablets</content>
                              <br/>
                              <content styleCode="bold">1,000 mg</content>
                              <br/>
                              <content styleCode="bold">3 times each day</content>
                           </td>
                           <td align="center" colspan="2" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">FERRIPROX Tablets</content>
                              <br/>
                              <content styleCode="bold">500 mg</content>
                              <br/>
                              <content styleCode="bold">3 times each day</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>Store at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                              </list>
                           </td>
                           <td colspan="3" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>Store at room temperature between 68°F to 77°F (20°C to 25°C).<br/>
                                 </item>
                                 <item>Store in the original bottle and tightly closed to protect from moisture.</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <list listType="unordered" styleCode="Disk">
                                 <item>Store at room temperature between 68°F to 77°F (20°C to 25°C).</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">Keep FERRIPROX Tablets and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of FERRIPROX Tablets.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use FERRIPROX Tablets for a condition for which it was not prescribed. Do not give FERRIPROX Tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about FERRIPROX Tablets that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in FERRIPROX Tablets?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">FERRIPROX Tablets</content>
                              <br/>
                              <content styleCode="bold">1,000 mg Twice-a-Day</content>
                              <br/>
                              <content styleCode="bold">2 times each day with food</content>
                           </td>
                           <td align="center" colspan="3" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">FERRIPROX Tablets</content>
                              <br/>
                              <content styleCode="bold">1,000 mg</content>
                              <br/>
                              <content styleCode="bold">3 times each day</content>
                           </td>
                           <td align="center" colspan="2" styleCode=" Toprule Lrule Rrule">
                              <content styleCode="bold">FERRIPROX Tablets</content>
                              <br/>
                              <content styleCode="bold">500 mg</content>
                              <br/>
                              <content styleCode="bold">3 times each day</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <content styleCode="bold">Active ingredient:</content> deferiprone<br/>
                              <content styleCode="bold">Inactive ingredients: </content>Tablet core: hypromellose acetate succinate, magnesium oxide, colloidal silicon dioxide and magnesium stearate. Coating: triethyl citrate, talc, titanium dioxide, and methacrylic acid and ethyl acrylate copolymer.</td>
                           <td colspan="3" styleCode=" Lrule Rrule">
                              <content styleCode="bold">Active ingredient:</content> deferiprone<br/>
                              <content styleCode="bold">Inactive ingredients: </content>Tablet core: methylcellulose, crospovidone, and magnesium stearate. Coating: hypromellose, hydroxypropyl cellulose, macrogol, and titanium dioxide.</td>
                           <td colspan="2" styleCode=" Lrule Rrule">
                              <content styleCode="bold">Active ingredient:</content> deferiprone<br/>
                              <content styleCode="bold">Inactive ingredients: </content>Tablet core: microcrystalline cellulose, magnesium stearate, colloidal silicon dioxide.<br/>Coating: hypromellose, polyethylene glycol, and titanium dioxide.</td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule Lrule Rrule">Distributed by: Chiesi USA, Inc., Cary, NC 27518.<br/>Manufactured by: Apotex Inc., Toronto, Ontario, Canada, M9L 1T9.<br/>CTFD-033-0521-00-SPL-1<br/>      <br/>For more information, call 1-888-661-9260.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration. 
		     
	Revised: 11/2021</paragraph>
               </text>
               <effectiveTime value="20230701"/>
            </section>
         </component>
         <component>
            <section ID="LINK_1afae025-47e9-4bdf-9537-707e3a0d181e">
               <id root="cafd1116-2ad7-487b-b1c0-f2b1d24af3e2"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Chiesi USA, Inc. </content>NDC 10122-104-01 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Ferriprox (deferiprone) tablets</content>
                  </paragraph>
                  <paragraph>1,000 mg </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>50 Tablets </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20230701"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Chiesi USA, Inc. NDC 10122-104-01 Ferriprox (deferiprone) tablets 1,000 mg Rx only 50 Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ferriprox-tablets-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_cfbe05da-cebb-4053-923a-a052f4ea67e7">
               <id root="118d2385-ca1c-4529-bf28-5a8ba8f68cd9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Chiesi USA, Inc. </content>NDC 10122-104-05 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Ferriprox (deferiprone) tablets</content>
                  </paragraph>
                  <paragraph>1,000 mg </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>50 Tablets </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20230701"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Chiesi USA, Inc. NDC 10122-104-05 Ferriprox (deferiprone) tablets 1,000 mg Rx only 50 Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ferriprox-tablets-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5000aede-29bd-4c4a-a554-0c67931bdd0a">
               <id root="ee52f3e1-c6e3-4c57-9387-99e772a83e11"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Chiesi USA, Inc. </content>NDC 10122-103-05 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Ferriprox (deferiprone) tablets</content>
                  </paragraph>
                  <paragraph>1,000 mg </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>50 Tablets </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20230701"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>Chiesi USA, Inc. NDC 10122-103-05 Ferriprox (deferiprone) tablets 1,000 mg Rx only 50 Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ferriprox-tablets-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5a5349cb-20a2-4bc8-a1f0-dd121bd73480">
               <id root="e812a510-eff3-4b76-8fe3-8bde857bfcda"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Chiesi USA, Inc.</content> NDC 10122-100-10 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Ferriprox (deferiprone) tablets</content>
                  </paragraph>
                  <paragraph>500 mg </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>100 Tablets </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20230701"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>Chiesi USA, Inc. NDC 10122-100-10 Ferriprox (deferiprone) tablets 500 mg Rx only 100 Tablets</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ferriprox-tablets-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>